Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Prochymal®
Mesenchymal Stem Cells · 1 trial · 1 indication
Changes in meniscal volume over the course of the study as determined by MRI
| Arm | Type | Description |
|---|---|---|
| Chondrogen - dose 1 | ACTIVE_COMPARATOR | Chondrogen - 50 million cells |
| Chondrogen - dose 2 | ACTIVE_COMPARATOR | Chondrogen - 150 million cells |
| Vehicle Control | OTHER | Vehicle Control |
| Name | Type | Description |
|---|---|---|
| Mesenchymal Stem Cells | DRUG | - |
| Hyaluronan | DRUG | - |
Inclusion Criteria: * Age 18 to 60, inclusive * In need of medial meniscectomy * Normal axial alignment * Stable knee- previous ligament reconstruction, if stable * Removal of at least 50% of the affected portion of the medial meniscus * Intact articular cartilage in posterior meniscal weight-beari...
Mesenchymal Stem Cells, developed by Mesoblast Limited, is being studied for recovery following partial medial meniscectomy, a knee surgery that removes part of a torn meniscus. The investigational cell therapy is intended to support healing after this procedure. It has been evaluated in a single completed Phase 1/2 clinical trial.
Mesenchymal Stem Cells is being developed by Mesoblast Limited, which trades under the ticker MESO. The company is the sponsor of the clinical program evaluating this cell therapy for recovery following partial medial meniscectomy.
Mesenchymal Stem Cells is in Phase 1 development. The program has one completed Phase 1/2 trial, and there are no active trials at this time. It is an investigational therapy and has not been approved by the FDA for any indication.
Mesenchymal Stem Cells has been studied in one completed clinical trial, NCT00225095, titled A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy. The trial enrolled 60 participants in the United States and evaluated recovery following partial medial meniscectomy.
The Phase 1/2 trial NCT00225095 was a randomized, double-blind, active-controlled study. It enrolled 60 participants aged 18 years and older of all sexes in the United States. The trial evaluated intra-articular injection of the cell therapy following partial medial meniscectomy and has been completed.